The Peptide Observer

Peptide research, explained for people who are not scientists.

Word

GIP receptor

Built from index records dated 2026-10-09 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works

One of the two docking points for the gut signals released after a meal. The other one is the GLP-1 receptor.

The second of the two after-a-meal locks.

How the research records put it

The glucose-dependent insulinotropic polypeptide receptor is the second incretin receptor. Tirzepatide is reported in its 2021 Lancet trial report as a dual GIP and GLP-1 receptor agonist.[1]

That paragraph is the reference wording, carried unchanged, with the record it came from. The plain sentence above it is this publication speaking, and it carries no citation because it adds nothing the reference wording does not hold.

Where this word turns up

4 entries in this index name this word in its records. None of them are described on this site; all are held back pending review.

It turns up on these group pages: Incretin receptor agonists.

Where this comes from

The record the reference wording is taken from.

  1. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022